National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Central China Sub-center of the National Center for Cardiovascular Diseases, Zhengzhou, China.
Lancet Public Health. 2022 Dec;7(12):e1041-e1050. doi: 10.1016/S2468-2667(22)00170-0.
China has been undergoing a rapid urbanisation. There are substantial disparities between old and new urban citizens in access to health care. We aimed to compare cardiovascular disease prevention and death risks among four distinct urban groups.
Urban residents aged 35-75 years living in 96 prefecture-level cities from 31 provinces in mainland China were enrolled in the national population-based cohort China Patient-centered Evaluative Assessment of Cardiac Events Million Persons Project. They were categorised into four groups by their former and current places of residence as follows: old-urban in situ residents (local residents in established urban areas since birth), new-urban in situ residents (local residents in newly urbanised areas established during urbanisation), urban-to-urban migrants (migrants from other urban areas), and rural-to-urban migrants (migrants from rural areas). We excluded participants with missing data for former and current places of residence, medical history, socioeconomic status, or lifestyle information. After adjusting for demographic and socioeconomic characteristics, relative risks (RRs) of cardiovascular disease prevention indicators and hazard ratios (HRs) of cardiovascular mortality and all-cause mortality of the other three population groups were estimated by modified log-Poisson models with robust standard error and Cox proportional hazard models, with old-urban in situ residents as the reference group.
From Sept 1, 2015, to Aug 17, 2020, 1 339 329 residents were enrolled, 270 606 were excluded for missing data in key variables, and 1 068 723 were subsequnetly included in the study. Compared with old-urban in situ residents, new-urban in situ residents were less likely to adhere to a healthy diet (RR 0·72 [95% CI 0·62-0·83]), while no significant results were observed in rural-to-urban migrants; new-urban in situ residents were less likely to use statins as primary prevention (RR 0·60 [0·46-0·79]), angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs; RR 0·78 [0·65-0·93]) and β-blockers (RR 0·68 [0·53-0·88]) as secondary prevention; and rural-to-urban migrants were less likely to use aspirin as a primary (RR 0·67 [0·46-0·96]) and secondary (RR 0·71 [0·54-0·94]) prevention and statins (RR 0·70 [0·51-0·97]) and ACEIs or ARBs (RR 0·68 [0·50-0·93]) as secondary prevention. Furthermore, in people diagnosed with hypertension, new-urban in situ residents were less likely to have their blood pressure controlled (RR 0·79 [95% CI 0·72-0·87]), while no significant results were observed in rural-to-urban migrants. New-urban in situ residents had higher risk of cardiovascular mortality (HR 1·16 [95% CI 1·05-1·29]; p=0·005) than did old-urban in situ residents, after a median follow-up of 2·7 years (IQR 2·0-4·2).
New-urban in situ residents and rural-to-urban migrants both showed poorer utilisation of primary and secondary prevention medications than did old-urban in situ residents, while new-urban in situ residents also had lower adherence to healthy lifestyles and higher death risks. Comprehensive measures should be taken to strengthen the primary health-care system in newly urbanised areas, and promote interprovincial medical insurance reimbursement.
Chinese Academy of Medical Sciences Innovation Fund for Medical Science and the National High Level Hospital Clinical Research Funding.
For the Chinese translation of the abstract see Supplementary Materials section.
中国正在经历快速的城市化进程。在获得医疗保健方面,新旧城市居民之间存在着巨大的差异。我们旨在比较四个不同城市群体的心血管疾病预防和死亡风险。
从 2015 年 9 月 1 日至 2020 年 8 月 17 日,我们招募了年龄在 35-75 岁之间、居住在中国大陆 31 个省 96 个地级市的城市居民,这些居民都参与了一项全国性的以人群为基础的队列研究——中国患者为中心的心血管事件评估百万人大项目。根据他们以前和现在的居住地,将他们分为四组:原地老城市居民(自出生以来就居住在已建成城市地区的当地居民)、原地新城市居民(城市化过程中新建城市地区的当地居民)、城市间移民(来自其他城市地区的移民)和农村向城市移民(来自农村地区的移民)。我们排除了有缺失以前和现在居住地、医疗史、社会经济地位或生活方式信息的参与者。在调整了人口统计学和社会经济特征后,采用修正的对数泊松模型和 Cox 比例风险模型,以原地老城市居民为参照组,估计了心血管疾病预防指标的相对风险(RR)和心血管死亡率和全因死亡率的危险比(HR)。
从 2015 年 9 月 1 日至 2020 年 8 月 17 日,共纳入 1339329 名居民,其中 270606 人因关键变量缺失数据被排除,随后有 1068723 人纳入研究。与原地老城市居民相比,原地新城市居民更不可能遵循健康饮食(RR 0.72[95%CI 0.62-0.83]),而农村向城市移民则没有显著差异;原地新城市居民更不可能将他汀类药物作为一级预防(RR 0.60[0.46-0.79])、血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)(RR 0.78[0.65-0.93])和β受体阻滞剂(RR 0.68[0.53-0.88]);农村向城市移民更不可能将阿司匹林作为一级(RR 0.67[0.46-0.96])和二级(RR 0.71[0.54-0.94])预防,以及他汀类药物(RR 0.70[0.51-0.97])和 ACEI 或 ARB(RR 0.68[0.50-0.93])作为二级预防;此外,在高血压患者中,原地新城市居民血压控制率较低(RR 0.79[95%CI 0.72-0.87]),而农村向城市移民则没有显著差异。原地新城市居民的心血管死亡率风险较高(HR 1.16[95%CI 1.05-1.29];p=0.005),而原地老城市居民的中位随访时间为 2.7 年(IQR 2.0-4.2)。
原地新城市居民和农村向城市移民在一级和二级预防药物的使用上都不如原地老城市居民,而原地新城市居民的健康生活方式依从性也较低,死亡风险较高。应采取综合措施,加强新建成城市地区的初级卫生保健系统,并促进省际医疗保险报销。
中国医学科学院创新基金医学科学和国家高水平医院临床研究资助。